Lewandowski Krzysztof Cezary, Kawalec Joanna, Kusiński Michał, Dąbrowska Katarzyna, Matusiak Aleksandra Ewa, Dudek Iga, Lewiński Andrzej
Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, 93-338 Lodz, Poland.
Department of Endocrinology and Metabolic Diseases, Polish Mother's Memorial Hospital-Research Institute, 93-338 Lodz, Poland.
J Clin Med. 2024 Jan 6;13(2):324. doi: 10.3390/jcm13020324.
Amiodarone-induced thyrotoxicosis (AIT) may pose treatment challenges. We present a series of patients in which we achieved the normalisation of free T3 (FT3) using intravenous methylprednisolone (ivMP) in AIT refractory to thiamazole and oral prednisone. Namely, in three males (aged 56, 50 and 64, all with a history of AF and/or a low ejection fraction), an addition of ivMP resulted in the normalisation of FT3, which allowed successful thyroidectomy. In another case of a 65-year-old man, we initially succeeded in the normalisation of FT3 using ivMP from FT4 > 7.77 ng/dL (0.93-1.7) to 2.41 ng/dL and in that of FT3 from 14.95 pg/mL (2-4.4) to 2.05 pg/mL), but four weeks after stopping ivMP, despite the continuation of thiamazole and prednisone, there was rebound thyrotoxicosis: FT4 > 7.77 ng/dL and FT3-5.46 pg/mL. Intravenous MP was restated leading to a decline in FT4 to 2.51 ng/dL and in FT3 to 1.92 pg/mL, thus allowing a successful thyroidectomy. Finally, in a 78-year-old man with AF, goitre, and AIT resistant to thiamazole, prednisone and lithium carbonate, we obtained a reduction in FT4 to 1.51 ng/dL and in FT3 to 3.17 pg/mL after seven pulses of ivMP. Oral prednisone was gradually reduced and successfully stopped about six months later. He remained on low-dose thiamazole (5 mg od).
Pulse ivMP in addition to oral steroids may be a useful adjunct therapy either for the preparation of a thyroidectomy or as a treatment modality in drug-resistant AIT. Though a total cure is possible, there is a danger of a rebound worsening of thyrotoxicosis after premature discontinuation of ivMP.
胺碘酮诱发的甲状腺毒症(AIT)可能带来治疗挑战。我们报告了一系列患者,在这些患者中,对于对甲巯咪唑和口服泼尼松难治的AIT,我们使用静脉注射甲泼尼龙(ivMP)使游离T3(FT3)恢复正常。具体而言,在三名男性患者(年龄分别为56岁、50岁和64岁,均有房颤病史和/或射血分数低)中,加用ivMP后FT3恢复正常,从而得以成功进行甲状腺切除术。在另一例65岁男性患者中,我们最初使用ivMP成功使FT3从FT4>7.77 ng/dL(0.93 - 1.7)降至2.41 ng/dL,FT3从14.95 pg/mL(2 - 4.4)降至2.05 pg/mL,但在停用ivMP四周后,尽管继续使用甲巯咪唑和泼尼松,仍出现甲状腺毒症反弹:FT4>7.77 ng/dL且FT3为5.46 pg/mL。再次使用静脉注射甲泼尼龙后,FT4降至2.51 ng/dL,FT3降至1.92 pg/mL,从而得以成功进行甲状腺切除术。最后,在一名78岁患有房颤、甲状腺肿且对甲巯咪唑、泼尼松和碳酸锂耐药的AIT男性患者中,经过七次ivMP脉冲治疗后,FT4降至1.51 ng/dL,FT3降至3.17 pg/mL。口服泼尼松逐渐减量,约六个月后成功停用。他继续服用低剂量甲巯咪唑(5 mg每日一次)。
除口服类固醇外,脉冲式ivMP可能是用于甲状腺切除术准备或作为耐药AIT治疗方式的有用辅助治疗。虽然有可能实现完全治愈,但过早停用ivMP存在甲状腺毒症反弹恶化的风险。